N
N. Wiedenmann
Researcher at University of Texas MD Anderson Cancer Center
Publications - 10
Citations - 423
N. Wiedenmann is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Head and neck cancer & Tumor hypoxia. The author has an hindex of 5, co-authored 10 publications receiving 408 citations. Previous affiliations of N. Wiedenmann include Technische Universität München.
Papers
More filters
Journal ArticleDOI
Hypoxia Imaging With FAZA-PET and Theoretical Considerations With Regard to Dose Painting for Individualization of Radiotherapy in Patients With Head and Neck Cancer
Anca L. Grosu,Michael Souvatzoglou,Barbara Röper,Martin Dobritz,N. Wiedenmann,Vesna Jacob,Hans-Jürgen Wester,Gerald Reischl,Hans Juergen Machulla,Markus Schwaiger,Michael Molls,Morand Piert,Morand Piert +12 more
TL;DR: This study demonstrates that FAZA-PET imaging could be used for a hypoxia-directed intensity-modulated radiotherapy approach in head and neck cancer.
Journal ArticleDOI
Current status of angiogenesis inhibitors combined with radiation therapy
TL;DR: Early results suggest that acute toxicity is acceptable, planned surgery after such treatment is feasible, and that further evaluation of such combined modality treatment is warranted.
Journal ArticleDOI
130-nm albumin - bound paclitaxel enhances tumor radiocurability and therapeutic gain
N. Wiedenmann,David Valdecanas,Nancy Hunter,Stephen Hyde,Thomas A. Buchholz,Luka Milas,Kathryn A. Mason +6 more
TL;DR: Preclinical findings show that combining nab-paclitaxel with radiotherapy would improve the outcome of taxane-based chemoradiotherapy, and this novel taxane is thus a good candidate for testing in clinical cheMoradiotherapy trials.
Journal ArticleDOI
Preclinical evaluation of erythropoietin administration in a model of radiation-induced kidney dysfunction.
Nicolaus Andratschke,Andrea Schnaitera,Wolfgang Weber,Lu Caia,Sabine Schill,N. Wiedenmann,Markus Schwaiger,Michael Molls,Carsten Nieder +8 more
TL;DR: In this paper, the role of growth factor erythropoietin (EPO) in kidney dysfunction was investigated in a C3H mouse model of unilateral kidney irradiation with 6, 8, and 10 Gy.
Journal ArticleDOI
Modulation of tumor radiation response with G3139, a bcl-2 antisense oligonucleotide
TL;DR: Investigation of in vivo anti-tumor effects of a combined modality treatment scheme consisting of radiation and the bcl-2 targeted AS oligonucleotide (ODN) G3139 (Oblimersen Sodium) found no significant effect on tumor cure as well as an ODN sequence specific effect.